These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8579915)

  • 1. Tissue-selective actions of estrogen analogs.
    Evans GL; Turner RT
    Bone; 1995 Oct; 17(4 Suppl):181S-190S. PubMed ID: 8579915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic guide to the mechanisms of antiestrogen action.
    MacGregor JI; Jordan VC
    Pharmacol Rev; 1998 Jun; 50(2):151-96. PubMed ID: 9647865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian status influences the skeletal effects of tamoxifen in adult rats.
    Sibonga JD; Evans GL; Hauck ER; Bell NH; Turner RT
    Breast Cancer Res Treat; 1996; 41(1):71-9. PubMed ID: 8932878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal effects of estrogen analogs.
    Lindsay R; Cosman F
    Osteoporos Int; 1997; 7 Suppl 1():S40-2. PubMed ID: 9205645
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective estrogen receptor modulators: a look ahead.
    Mitlak BH; Cohen FJ
    Drugs; 1999 May; 57(5):653-63. PubMed ID: 10353293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of anti-estrogens on bone in castrated and intact female rats.
    Jordan VC; Phelps E; Lindgren JU
    Breast Cancer Res Treat; 1987 Oct; 10(1):31-5. PubMed ID: 3689979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical potential of new antiestrogens.
    Gradishar WJ; Jordan VC
    J Clin Oncol; 1997 Feb; 15(2):840-52. PubMed ID: 9053512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen exerts agonistic effects on clusterin and complement C3 gene expression in RUCA-I primary xenografts and metastases but not normal uterus.
    Zierau O; O'Sullivan J; Morrissey C; McDonald D; Wünsche W; Schneider MR; Tenniswood MP; Vollmer G
    Endocr Relat Cancer; 2004 Dec; 11(4):823-30. PubMed ID: 15613455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen and ICI 182,780 interactions with thyroid hormone in the ovariectomized-thyroidectomized rat.
    Dipippo VA; Powers CA
    J Pharmacol Exp Ther; 1997 Apr; 281(1):142-8. PubMed ID: 9103491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
    Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
    Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-implantation activity of antiestrogens and mifepristone.
    Dao B; Vanage G; Marshall A; Bardin CW; Koide SS
    Contraception; 1996 Oct; 54(4):253-8. PubMed ID: 8922879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer.
    Nicholson RI; Gee JM; Manning DL; Wakeling AE; Montano MM; Katzenellenbogen BS
    Ann N Y Acad Sci; 1995 Jun; 761():148-63. PubMed ID: 7625718
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
    Tobias JS
    Int J Biochem Cell Biol; 2004 Nov; 36(11):2112-9. PubMed ID: 15313457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.